Low Serum Concentration of Obestatin as a Predictor of Mortality in Maintenance Hemodialysis Patients

Abstract EN

Obestatin, a proposed anorexigenic gut hormone, has been shown to have a number of beneficial cardiotropic effects in experimental studies.

We hypothesized that obestatin alteration in hemodialysis patients may link to clinical outcomes.

This cross-sectional study with prospective followup for almost 4 years was performed on 94 prevalent hemodialysis patients.

Obestatin, leptin, proinflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin-6, and various nutritional markers were measured.

Patients with low obestatin levels, defined as a level less than median, had a worse all-cause mortality and cardiovascular mortality.

The crude all-cause (HR 2.23, 95% CI 1.17 to 4.24) and cardiovascular mortality hazard ratios (HR 4.03, 95% CI 1.27 to 12.76) in these patients continued to be significant after adjustment for various confounders for all-cause mortality.

Across the four obestatin-TNF-α categories, the group with low obestatin and high TNF-α (above median level) exhibited a worse outcome in both all-cause mortality and cardiovascular mortality.

Clinical characteristics of patients in low obestatin high TNF-α group did not differ from other obestatin-TNF-α categorized groups.

In summary, low serum obestatin concentration is an independent predictor of mortality in prevalent hemodialysis patients.

Novel interactions were observed between obestatin and TNF-α, which were associated with mortality risk, especially those due to cardiovascular causes.